U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937866) titled 'Maintenance Zanzalintinib With Etoposide After HDCT in GCT' on April 14.
Brief Summary: This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Germ Cell Tumor
Intervention:
DRUG: Zanzalintinib
Three zanzalintinib doses of 40mg, 60mg or 100mg. The initial starting dose of zanzalintinib will be 40mg. The patients will receive zanzalintinib orally daily continuous...